Randomized clinical trial: A double‐blind, proof‐of‐concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro‐esophageal reflux disease and partial response to a healing dose of a proton‐pump inhibitor
Neurogastroenterology & Motility2022Vol. 35(1), pp. e14468–e14468
Citations Over TimeTop 10% of 2022 papers
Jan Tack, Borislav Vladimirov, Ivo Horný, Chui Fung Chong, J Eisner, Richard Czerniak, Yohei Takanami
Abstract
No statistically significant difference in efficacy and safety was observed among treatment groups, and vonoprazan was well tolerated. The trial is registered with the National Board of Health (EudraCT: 2015-001154-14) database.
Related Papers
- → Partial symptom‐response to proton pump inhibitors in patients with non‐erosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients(2012)69 cited
- → Heartburn severity can predict pathologic oesophageal reflux in gastro‐oesophageal reflux disease patients treated with a proton‐pump inhibitor(2003)6 cited
- Clinical Effect of Esomeprazole on Gastroesophageal Reflux Disease(2010)
- Oesophageal acid exposure test in extraesophageal symptoms of GERD and efficacy of esomeprazole treatment(2008)